Pharmafile Logo
Pharmafocus logo
Advanced Search

psoriasis

Showing 15 posts of 67 posts found.

Boehringer Ingelheim’s Spevigo gains additional approvals in US and China

March 20, 2024
Medical Communications Boehringer Ingelheim, Dermatology, FDA, Spevigo, psoriasis

Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and Drug Administration (FDA) for the …

News

Bristol Myers Squibb’s Sotyktu recommended for NHS use for adult patients with psoriasis

June 28, 2023
Medical Communications Dermatology, NHS, Sotyktu, bristol myers squibb, psoriasis

Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Sotyktu (deucravacitinib) …

News
Bristol Myers Squibb building in New Jersey

Bristol Myers Squibb psoriasis drug shows positive Phase III results

April 29, 2021
Bristol-Myers Squibb, bristol myers squibb, pharma, pharma news, psoriasis, psoriasis treatment

Bristol Myers Squibb’s investigational deucravacitinib drug, for the treatment of moderate-to-severe plaque psoriasis, has shown positive results in two Phase …

News
Lab testing

Lipidor to begin Phase III trial on psoriasis treatment

April 22, 2021
Phase III trials, lipidor, pharma, pharma news, psoriasis

Lipidor has submitted an application with the Indian Medical Products Agency to begin a Phase III trial on their drug …

News
cream-4713579_1920

Dermavant announces positive Phase III findings for psoriasis treatment tapinarof

February 19, 2021
Medical Communications Dermavant Sciences, psoriasis

Dermavant Sciences has announced positive safety and efficacy results from a planned interim analysis of PSOARING 3, a long-term, open-label …

News
almirall-605x338

MC2 Therapeutics grants Almirall European commercial rights for psoriasis cream Wynzora

February 18, 2021
Almirall, MC2 Therapeutics, psoriasis

Biopharma company Almirall and MC2 Therapeutics, a pharmaceutical company focused on therapies for autoimmune and chronic inflammatory conditions, have announced …

News
novartis_outside_1

Novartis’ Cosentyx gets European go-ahead in paediatric plaque psoriasis

August 3, 2020
Sales and Marketing Cosentyx, Europe, Novartis, pharma, psoriasis

Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) has chalked up approval from the European Commission (EC) for the treatment of patients …

News

UCB’s investigational IL-17A and IL-17F inhibitor outclasses Novartis’ Cosentyx in plaque psoriasis

July 24, 2020
Medical Communications, Research and Development Cosentyx, UCB, pharma, psoriasis

UCB has revealed promising new data from a head-to-head trial pitting the company’s IL-17A and IL-17F inhibitor bimekizumab against Novartis’ …

News
abbvie_0

AbbVie’s Skyrizi outpaces Novartis’ Cosentyx in plaque psoriasis skin clearance

January 16, 2020
Research and Development AbbVie, Cosentyx, Novartis, Skyrizi, pharma, psoriasis

AbbVie has made it known that Skyrizi (risankizumab) outpaced Novartis’ Cosentyx (secukinumab) at Phase 3 in the treatment of plaque …

News
lilly_building_with_american_flag_web

Lilly’s Taltz beats Janssen’s Tremfya at Phase 4 in plaque psoriasis

August 15, 2019
Research and Development Eli Lilly, Taltz, Tremfya, pharma, psoriasis

Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s …

News
novartis_side_building

Novartis provides promising update on Cosentyx in plaque psoriasis

June 26, 2019
Research and Development Cosentyx, Novartis, pharma, psoriasis

Novartis has revealed brief new data on its IL-17A antibody Cosentyx (secukinumab) in the treatment off plaque psoriasis, showing that …

News
bms_nassau_park_new_jersey

Bristol-Myers Squibb to sell off Celgene’s Otezla ahead of $74 billion merger

June 24, 2019
Manufacturing and Production Bristol-Myers Squibb, Celgene, FTC, otezla, pharma, psoriasis

Bristol-Myers Squibb has agreed to sell off Celgene’s psoriasis treatment Otezla, to appease antitrust regulators. BMS will divest one of …

News

New Phase 3 data confirms safety and efficacy of UCB’s Cimzia in plaque and psoriatic arthritis

April 30, 2019
Manufacturing and Production, Research and Development Cimzia, UCB Pharma, pharma, plaque psoriasis, psoriasis

New Phase 3 data has been released by UCB Pharma on the safety of Cimzia (certolizumab pegol) in the treatment …

News
abbvie_0

AbbVie’s Skyrizi snatches up FDA approval in moderate to severe plaque psoriasis

April 24, 2019
Research and Development, Sales and Marketing AbbVie, FDA, Skyrizi, US, pharma, psoriasis

AbbVie has revealed that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab-rzaa) has received marketing authorisation in the US from the FDA …

News

NICE recommends UCB’s Cimzia in severe plaque psoriasis

April 18, 2019
Sales and Marketing Cimzia, NICE, UCB Pharma, UK, pharma, plaque psoriasis, psoriasis

NICE has announced its decision to recommend UCB Pharma’s Cimzia (certolizumab pegol) for use on the NHS in England in …

News

Latest content

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024

ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial

June 25, 2024

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024